美罗培南-克拉维酸对多重耐药结核分枝杆菌具有较高的体外活性。
Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
作者信息
Davies Forsman L, Giske C G, Bruchfeld J, Schön T, Juréen P, Ängeby K
机构信息
Unit of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden
Department of Clinical Microbiology, Karolinska University Hospital, Solna, Sweden Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
出版信息
Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.
Abstract
We investigated the activity of meropenem-clavulanic acid (MEM-CLA) against 68 Mycobacterium tuberculosis isolates. We included predominantly multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) isolates, since the activity of MEM-CLA for resistant isolates has previously not been studied extensively. Using Middlebrook 7H10 medium, all but four isolates showed an MIC distribution of 0.125 to 2 mg/liter for MEM-CLA, below the non-species-related breakpoint for MEM of 2 mg/liter defined by EUCAST. MEM-CLA is a potential treatment option for MDR/XDR-TB.
摘要
我们研究了美罗培南-克拉维酸（MEM-CLA）对68株结核分枝杆菌分离株的活性。我们纳入的主要是多重耐药和广泛耐药结核病（MDR/XDR-TB）分离株，因为此前尚未对MEM-CLA对耐药分离株的活性进行广泛研究。使用Middlebrook 7H10培养基，除4株分离株外，所有分离株对MEM-CLA的最低抑菌浓度（MIC）分布为0.125至2毫克/升，低于欧洲抗菌药物敏感性试验委员会（EUCAST）定义的MEM非种属相关折点2毫克/升。MEM-CLA是MDR/XDR-TB的一种潜在治疗选择。
相似文献
1
Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2015;59(6):3630-2. doi: 10.1128/AAC.00171-15. Epub 2015 Mar 30.
2
Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Int J Mycobacteriol. 2015 Mar;4 Suppl 1:80-1. doi: 10.1016/j.ijmyco.2014.10.018. Epub 2014 Nov 11.
3
Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
J Antimicrob Chemother. 2013 Feb;68(2):366-9. doi: 10.1093/jac/dks395. Epub 2012 Oct 15.
4
In Vitro Evaluation of Linezolid and Meropenem Against Clinical Isolates of Multi Drug Resistant Tuberculosis By Mycobacterial Growth Indicator Tube (MGIT) 960.
J Coll Physicians Surg Pak. 2015 Jun;25(6):427-30.
5
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):393-9. doi: 10.1128/AAC.01035-15. Print 2016 Jan.
6
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
J Antimicrob Chemother. 2017 Jun 1;72(6):1678-1687. doi: 10.1093/jac/dkx022.
7
Comparison of Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00165-18. Print 2018 Aug.
8
Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
Antimicrob Agents Chemother. 2013 Dec;57(12):6085-96. doi: 10.1128/AAC.01253-13. Epub 2013 Sep 23.
9
Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol.
J Antimicrob Chemother. 1998 Dec;42(6):735-40. doi: 10.1093/jac/42.6.735.
10
Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
Int J Antimicrob Agents. 2014 Mar;43(3):231-5. doi: 10.1016/j.ijantimicag.2013.12.007. Epub 2013 Dec 31.
引用本文的文献
1
Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.
BMC Infect Dis. 2025 Apr 28;25(1):619. doi: 10.1186/s12879-025-10730-y.
2
activity of new combinations of β-lactam and β-lactamase inhibitors against the complex.
Microbiol Spectr. 2023 Sep 22;11(5):e0178123. doi: 10.1128/spectrum.01781-23.
3
A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis.
J Clin Tuberc Other Mycobact Dis. 2017 Dec 6;10:9-16. doi: 10.1016/j.jctube.2017.12.004. eCollection 2018 Jan.
4
Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis.
Front Microbiol. 2019 Feb 11;10:190. doi: 10.3389/fmicb.2019.00190. eCollection 2019.
5
Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant .
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01489-18. Print 2019 Feb.
6
Phosphate Promotes the Recovery of Mycobacterium tuberculosis β-Lactamase from Clavulanic Acid Inhibition.
Biochemistry. 2017 Nov 28;56(47):6257-6267. doi: 10.1021/acs.biochem.7b00556. Epub 2017 Nov 14.
7
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
J Antimicrob Chemother. 2017 Jun 1;72(6):1678-1687. doi: 10.1093/jac/dkx022.
8
Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):163-72. doi: 10.1093/trstmh/trv107.
本文引用的文献
1
Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2014 Dec;58(12):7557-9. doi: 10.1128/AAC.02995-14. Epub 2014 Sep 22.
2
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
Clin Infect Dis. 2013 Jan;56(2):236-44. doi: 10.1093/cid/cis856. Epub 2012 Oct 16.
3
Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
J Antimicrob Chemother. 2013 Feb;68(2):366-9. doi: 10.1093/jac/dks395. Epub 2012 Oct 15.
4
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
Eur Respir J. 2013 Jun;41(6):1386-92. doi: 10.1183/09031936.00124312. Epub 2012 Sep 20.
5
Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.
Antimicrob Agents Chemother. 2012 Jun;56(6):3384-7. doi: 10.1128/AAC.05690-11. Epub 2012 Mar 26.
6
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2012 Apr;16(4):558-60. doi: 10.5588/ijtld.11.0414.
7
Activity of carbapenems combined with clavulanate against murine tuberculosis.
Antimicrob Agents Chemother. 2011 Jun;55(6):2597-600. doi: 10.1128/AAC.01824-10. Epub 2011 Mar 14.
8
Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.
Pediatr Infect Dis J. 2011 Sep;30(9):812-3. doi: 10.1097/INF.0b013e3182154b05.
9
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
J Antimicrob Chemother. 2009 Oct;64(4):786-93. doi: 10.1093/jac/dkp262. Epub 2009 Jul 23.
10
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
Science. 2009 Feb 27;323(5918):1215-8. doi: 10.1126/science.1167498.
Zotero 插件